Revenue Summary of Cellectis S.A.

Cellectis S.A.'s latest annual revenue in 2023 was 755 Thousand USD , down -95.98% from previous year.
Cellectis S.A.'s latest quarterly revenue in 2024 Q1 was 4.5 Million USD , up 1449.83% from previous quarter.
Cellectis S.A. reported a annual revenue of 19.17 Million USD in annual revenue 2022, down -74.08% from previous year.
Cellectis S.A. reported a annual revenue of 73.94 Million USD in annual revenue 2021, down 0.0% from previous year.
Cellectis S.A. reported a quarterly revenue of 8.02 Million USD for 2024 Q2, up 78.17% from previous quarter.
Cellectis S.A. reported a quarterly revenue of 139 Thousand USD for 2023 Q1, down -99.13% from previous quarter.

Annual Revenue Chart of Cellectis S.A. (2023 - 2007)

Historical Annual Revenue of Cellectis S.A. (2023 - 2007)

Year	Revenue	Revenue Growth
2023	755 Thousand USD	-95.98%
2022	19.17 Million USD	-74.08%
2021	73.94 Million USD	0.0%
2020	73.94 Million USD	386.83%
2019	15.19 Million USD	19.32%
2018	12.73 Million USD	-49.46%
2017	25.18 Million USD	-40.85%
2016	42.58 Million USD	-22.63%
2015	55.04 Million USD	109.3%
2014	26.29 Million USD	15.26%
2013	22.81 Million USD	-17.97%
2012	27.81 Million USD	34.19%
2011	20.72 Million USD	-1.2%
2010	20.98 Million USD	21.14%
2009	17.31 Million USD	17.26%
2008	14.77 Million USD	260.13%
2007	4.1 Million USD	0.0%

Year	Revenue	Revenue Growth
2024 Q1	4.5 Million USD	1449.83%
2024 Q2	8.02 Million USD	78.17%
2023 Q1	139 Thousand USD	-99.13%
2023 Q3	155 Thousand USD	-12.92%
2023 Q4	290.45 Thousand USD	87.39%
2023 Q2	178 Thousand USD	28.06%
2023 FY	770.79 Thousand USD	-95.98%
2022 Q4	16.02 Million USD	7284.33%
2022 Q1	1.69 Million USD	-87.57%
2022 Q2	1.34 Million USD	-20.57%
2022 Q3	217 Thousand USD	-83.9%
2022 FY	19.17 Million USD	-74.08%
2021 Q4	13.64 Million USD	64.21%
2021 Q1	25.6 Million USD	87.57%
2021 FY	73.94 Million USD	0.0%
2021 Q2	11.17 Million USD	-56.35%
2021 Q3	8.31 Million USD	-25.63%
2020 Q1	50.12 Million USD	1033.37%
2020 FY	73.94 Million USD	386.83%
2020 Q2	2.9 Million USD	-94.21%
2020 Q3	6.18 Million USD	113.1%
2020 Q4	13.64 Million USD	120.86%
2019 Q4	4.42 Million USD	-47.89%
2019 Q3	8.48 Million USD	636.81%
2019 FY	15.19 Million USD	19.32%
2019 Q2	1.15 Million USD	11.2%
2019 Q1	1.03 Million USD	7.02%
2018 Q4	968 Thousand USD	6.96%
2018 FY	12.73 Million USD	-49.46%
2018 Q3	905 Thousand USD	-82.08%
2018 Q2	5.04 Million USD	-16.41%
2018 Q1	6.04 Million USD	5.5%
2017 FY	25.18 Million USD	-40.85%
2017 Q1	6.76 Million USD	-15.39%
2017 Q2	6.75 Million USD	-0.16%
2017 Q3	6.12 Million USD	-9.32%
2017 Q4	5.72 Million USD	-6.48%
2016 Q4	7.99 Million USD	-29.41%
2016 FY	42.58 Million USD	-22.63%
2016 Q2	17.6 Million USD	122.57%
2016 Q1	7.9 Million USD	-73.2%
2016 Q3	11.32 Million USD	-35.68%
2015 Q1	9.12 Million USD	-6.77%
2015 Q4	29.5 Million USD	245.08%
2015 FY	55.04 Million USD	109.3%
2015 Q3	8.55 Million USD	4.04%
2015 Q2	8.21 Million USD	-9.95%
2014 FY	26.29 Million USD	15.26%
2014 Q4	9.78 Million USD	-4.09%
2014 Q3	10.2 Million USD	45.1%
2014 Q2	7.03 Million USD	-0.64%
2014 Q1	7.08 Million USD	36.52%
2013 Q2	3.37 Million USD	1.46%
2013 FY	22.81 Million USD	-17.97%
2013 Q1	3.32 Million USD	0.0%
2013 Q3	5.09 Million USD	51.04%
2013 Q4	5.18 Million USD	1.75%
2012 FY	27.81 Million USD	34.19%
2012 Q4	- USD	0.0%
2011 Q4	- USD	0.0%
2011 FY	20.72 Million USD	-1.2%
2010 FY	20.98 Million USD	21.14%
2009 FY	17.31 Million USD	17.26%
2008 FY	14.77 Million USD	260.13%
2007 FY	4.1 Million USD	0.0%

Peer Revenue Comparison of Cellectis S.A.

Name	Revenue	Revenue Difference
Burzynski Research Institute, Inc.	- USD	-Infinity%
Arch Therapeutics, Inc.	75.72 Thousand USD	-897.042%
Evofem Biosciences, Inc.	18.21 Million USD	95.856%
Nascent Biotech, Inc.	- USD	-Infinity%
Rebus Holdings, Inc.	- USD	-Infinity%
Santhera Pharmaceuticals Holding AG	122.95 Million USD	99.386%
Qrons Inc.	- USD	-Infinity%
Adynxx, Inc.	- USD	-Infinity%
Neon Bloom, Inc.	- USD	-Infinity%
Northwest Biotherapeutics, Inc.	1.93 Million USD	60.921%
ProtoKinetix, Incorporated	- USD	-Infinity%
Skye Bioscience, Inc.	- USD	-Infinity%
Eiger BioPharmaceuticals, Inc.	15.77 Million USD	95.213%
Nanobac Pharmaceuticals, Incorporated	17.62 Thousand USD	-4184.66%
Institute of Biomedical Research Corp.	- USD	-Infinity%
SQZ Biotechnologies Company	21.47 Million USD	96.485%
Intellipharmaceutics International Inc.	65.72 Thousand USD	-1048.673%
Propanc Biopharma, Inc.	- USD	-Infinity%
Mesoblast Limited	5.9 Million USD	87.208%
Marizyme, Inc.	645.81 Thousand USD	-16.907%
Genus plc	668.8 Million USD	99.887%
VioQuest Pharmaceuticals, Inc.	- USD	-Infinity%
Pharming Group N.V.	245.31 Million USD	99.692%
Therapeutic Solutions International, Inc.	98.99 Thousand USD	-662.672%
CNBX Pharmaceuticals Inc.	410.16 Thousand USD	-84.072%
Nymox Pharmaceutical Corporation	- USD	-Infinity%
ContraFect Corporation	- USD	-Infinity%
PsyBio Therapeutics Corp.	- USD	-Infinity%
Sienna Biopharmaceuticals, Inc.	- USD	-Infinity%
RegeneRx Biopharmaceuticals, Inc.	76.76 Thousand USD	-883.572%
IMV Inc.	- USD	-Infinity%
AXIM Biotechnologies, Inc.	39.51 Thousand USD	-1810.522%
MultiCell Technologies, Inc.	49.32 USD	-1530719.14%
ONE Bio Corp.	52.29 Million USD	98.556%
Accustem Sciences Inc.	- USD	-Infinity%
RVL Pharmaceuticals plc	49.72 Million USD	98.482%
Arno Therapeutics, Inc.	- USD	-Infinity%
EV Biologics, Inc.	48.9 Thousand USD	-1443.967%
Q BioMed Inc.	284.35 Thousand USD	-165.516%
Emmaus Life Sciences, Inc.	29.59 Million USD	97.449%
Mosaic ImmunoEngineering Inc.	- USD	-Infinity%
Biomind Labs Inc.	- USD	-Infinity%
American Oriental Bioengineering, Inc.	145.09 Million USD	99.48%
Provectus Biopharmaceuticals, Inc.	557.71 Thousand USD	-35.375%
TetraLogic Pharmaceuticals Corporation	- USD	-Infinity%
Oncotelic Therapeutics, Inc.	70 Thousand USD	-978.571%
GlobeStar Therapeutics Corporation	- USD	-Infinity%
THC Farmaceuticals, Inc.	- USD	-Infinity%
Acro Biomedical Co., Ltd.	658.5 Thousand USD	-14.655%
Curative Biotechnology, Inc.	- USD	-Infinity%
GB Sciences, Inc.	- USD	-Infinity%
Alpha Cognition Inc.	- USD	-Infinity%
HST Global, Inc.	- USD	-Infinity%
CSL Limited	14.69 Billion USD	99.995%
Wesana Health Holdings Inc.	- USD	-Infinity%
Halberd Corporation	999.00 USD	-75475.576%
Enzolytics Inc.	52.79 Thousand USD	-1330.033%
Agentix Corp.	- USD	-Infinity%
Resverlogix Corp.	- USD	-Infinity%
Nuo Therapeutics, Inc.	608.52 Thousand USD	-24.07%
MetaStat, Inc.	- USD	-Infinity%
argenx SE	1.22 Billion USD	99.938%
Enzon Pharmaceuticals, Inc.	- USD	-Infinity%
Endonovo Therapeutics, Inc.	140.24 Thousand USD	-438.355%
RespireRx Pharmaceuticals Inc.	- USD	-Infinity%
GeneThera, Inc.	- USD	-Infinity%
Inhibitor Therapeutics, Inc.	- USD	-Infinity%
AVAX Technologies, Inc.	617.38 Thousand USD	-22.29%
Zenith Capital Corp.	- USD	-Infinity%
Genscript Biotech Corporation	839.52 Million USD	99.91%
Ember Therapeutics, Inc.	- USD	-Infinity%
Anthera Pharmaceuticals, Inc.	- USD	-Infinity%
Sigyn Therapeutics, Inc.	- USD	-Infinity%
WPD Pharmaceuticals Inc.	- USD	-Infinity%
Cotinga Pharmaceuticals Inc.	- USD	-Infinity%
Kadimastem Ltd	- USD	-Infinity%
Helix BioMedix, Inc.	997.72 Thousand USD	24.328%
VitaSpring Biomedical Co. Ltd.	- USD	-Infinity%
Capstone Therapeutics Corp.	48.35 Million USD	98.439%
BioStem Technologies, Inc.	16.68 Million USD	95.475%
Oncology Pharma Inc.	- USD	-Infinity%
Reve Technologies, Inc.	- USD	-Infinity%
LadRx Corporation	- USD	-Infinity%
Cell Source, Inc.	- USD	-Infinity%
Regen BioPharma, Inc.	236.56 Thousand USD	-219.158%
Regen BioPharma, Inc.	236.56 Thousand USD	-219.158%
NovAccess Global Inc.	- USD	-Infinity%
Affymax, Inc.	1.36 Million USD	44.85%
Itoco Inc.	- USD	-Infinity%
Rasna Therapeutics, Inc.	- USD	-Infinity%
Pathfinder Cell Therapy, Inc.	- USD	-Infinity%
Mobile Lads Corp.	- USD	-Infinity%
CytoDyn Inc.	- USD	-Infinity%
Claritas Pharmaceuticals, Inc.	- USD	-Infinity%
NDT Pharmaceuticals Inc.	- USD	-Infinity%
NanoSphere Health Sciences Inc.	- USD	-Infinity%
Alseres Pharmaceuticals, Inc.	473.73 Thousand USD	-59.373%
SYBLEU INC	11.69 Thousand USD	-6355.198%
Advanced Proteome Therapeutics Corporation	- USD	-Infinity%
ImmunoCellular Therapeutics, Ltd.	- USD	-Infinity%
International Stem Cell Corporation	7.78 Million USD	90.307%
Bioxytran, Inc.	- USD	-Infinity%
GlobeImmune, Inc.	- USD	-Infinity%
Predictive Technology Group, Inc.	- USD	-Infinity%
ProText Mobility, Inc.	- USD	-Infinity%
Cardax, Inc.	- USD	-Infinity%
VG Life Sciences Inc.	- USD	-Infinity%
Kaleido Biosciences, Inc.	- USD	-Infinity%
Advaxis, Inc.	13 Thousand USD	-5707.692%
Adhera Therapeutics, Inc.	- USD	-Infinity%
RenovaCare, Inc.	- USD	-Infinity%
Regnum Corp.	- USD	-Infinity%
Innovation Pharmaceuticals Inc.	- USD	-Infinity%
Neutra Corp.	39.53 Thousand USD	-1809.749%
Windtree Therapeutics, Inc.	- USD	-Infinity%
PureTech Health plc	3.33 Million USD	77.327%
Coeptis Therapeutics, Inc.	- USD	-Infinity%
IXICO plc	6.66 Million USD	88.672%
IntelGenx Technologies Corp.	1.03 Million USD	27.334%
Gelesis Holdings, Inc.	25.76 Million USD	97.07%
CSL Limited	14.8 Billion USD	99.995%

Global Stocks Search

Cellectis S.A. (CMVLF)

Revenue Summary of Cellectis S.A.

Annual Revenue Chart of Cellectis S.A. (2023 - 2007)

Historical Annual Revenue of Cellectis S.A. (2023 - 2007)

Peer Revenue Comparison of Cellectis S.A.